Thank you. That's a great question.
We have a very robust pandemic plan at Hoffmann-La Roche. The objectives really are to protect the health and safety of our workers, to ensure business continuity, and then to ensure a recovery of business. The plan does include both treatment and preventative strategies. Our feeling is that treatment is important, but prevention is key to ensuring that there's no absenteeism or that it minimizes absenteeism and we can continue to operate.
Obviously, when we talk to other corporations, they're very interested in what our plan is, and we share that with them. As I said in my brief, one of their biggest challenges is understanding what kind of support they are going to receive from government; will they have access to the current stockpile of antivirals that exist or not? At this point in time, we're not able to really respond to that, and that's really the nature of our second recommendation.